RE-LY trial

The RE-LY trial was a large clinical study comparing a medication called dabigatran to the traditional blood thinner warfarin for preventing blood clots and strokes in patients with atrial fibrillation (irregular heartbeat). It found that dabigatran was as effective as warfarin in reducing strokes, but with a lower risk of certain bleeding complications. The study helped establish dabigatran as a safe and effective alternative for stroke prevention in this population, offering patients more options and potentially fewer monitoring requirements.